SWITCH A Randomised Sequential Openlabel Study to Evaluate

SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer Christian Eichelberg, Walter L. Vervenne, Maria De Santis, Ludwig Fischer von Weikersthal, Peter J. Goebell, Christian Lerchenmüller, Uwe Zimmermann, Monique M. E. M. Bos, Werner Freier, Silke Schirrmacher-Memmel, Michael Staehler, Sascha Pahernik, Maartje Los, Marcus Schenck, Anne Flörcken, Cornelis van Arkel, Kirsten Hauswald, Martin Indorf, Dana Gottstein, Maurice S. Michel European Urology Volume 68 Issue 5 Pages 837 -847 (November 2015) DOI: 10. 1016/j. eururo. 2015. 04. 017 Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 1 European Urology 2015 68837 -847 DOI: (10. 1016/j. eururo. 2015. 04. 017) Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 2 European Urology 2015 68837 -847 DOI: (10. 1016/j. eururo. 2015. 04. 017) Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 3 European Urology 2015 68837 -847 DOI: (10. 1016/j. eururo. 2015. 04. 017) Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 4 European Urology 2015 68837 -847 DOI: (10. 1016/j. eururo. 2015. 04. 017) Copyright © 2015 European Association of Urology Terms and Conditions